DeepMed Research

ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Not Applicable

Recruiting

Conditions: Breast Cancer
Prostate Cancer
Liver Cancer

Interventions: Behavioral: Match-list intervention
Behavioral: Clinical trial match-list

First Posted Date: 2021-12-06

Last Posted Date: 2025-02-20

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 644

Registration Number: NCT05146297

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Herbert Irving Comprehensive Cancer Care Center, NYC, New York, United States

Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI

Completed

Conditions: Contrast-induced Nephropathy

Interventions: Procedure: Percutaneous Coronary Intervention

First Posted Date: 2021-11-24

Last Posted Date: 2021-11-24

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 14616

Registration Number: NCT05132062

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Pelvic Floor Disorder Education in Prenatal Care

Not Applicable

Completed

Conditions: Pelvic Floor Disorders

Interventions: Other: Education Video

First Posted Date: 2021-11-19

Last Posted Date: 2022-05-27

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 94

Registration Number: NCT05127512

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Phase 1

Active, not recruiting

Conditions: Ulcerative Colitis (Disorder)

Interventions: Drug: Hydroxychloroquine
Drug: Mesalamine

First Posted Date: 2021-11-12

Last Posted Date: 2025-02-11

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 3

Registration Number: NCT05119140

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York, New York, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

Intramuscular Ketamine for Suicidal Ideation

Phase 2

Withdrawn

Conditions: Suicidal Ideation

Interventions: Drug: Ketamine (Ketalar)
Drug: Placebo

First Posted Date: 2021-11-03

Last Posted Date: 2022-04-05

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Registration Number: NCT05105061

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

Phase 2

Conditions: Neoplasm
Skull Base Neoplasm

Interventions: Drug: 5-Aminolevulinic acid Hydrochloride

First Posted Date: 2021-11-01

Last Posted Date: 2024-11-19

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 7

Registration Number: NCT05101798

Locations: 🇺🇸
Mount Sinai Union Square, New York, New York, United States
🇺🇸
New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Metastasis

Interventions: Drug: Abemaciclib
Drug: Bicalutamide

First Posted Date: 2021-10-27

Last Posted Date: 2025-04-02

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 42

Registration Number: NCT05095207

Locations: 🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸
Mount Sinai - West, New York, New York, United States
🇺🇸
Dubin breast Center, New York, New York, United States

Integrated Intervention for Breast Cancer Survivors With Diabetes

Not Applicable

Completed

Conditions: Diabetes
Breast Cancer

Interventions: Behavioral: Integrated Intervention for Breast Cancer Survivors with Diabetes
Behavioral: Attention Control

First Posted Date: 2021-10-25

Last Posted Date: 2023-10-23

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 59

Registration Number: NCT05092477

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Northwell Health, New Hyde Park, New York, United States

Increasing Breast Cancer Screening in Chinese Immigrants

Not Applicable

Completed

Conditions: Screening Mammogram

Interventions: Behavioral: Narrative breast health education

First Posted Date: 2021-10-22

Last Posted Date: 2024-06-10

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 99

Registration Number: NCT05089292

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

JAK Inhibition in Food Allergy

Phase 1

Recruiting

Conditions: Food Allergy

Interventions: Drug: Abrocitinib

First Posted Date: 2021-10-06

Last Posted Date: 2024-11-11

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 40

Registration Number: NCT05069831

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy